Table 2.
Review of Similar Reports in the Literature
| Parameters | Hesse et al., NEJM 200714 | Jadhav et al., JCEM 201415 | ||
|---|---|---|---|---|
| Cases | Case 1 | Case 1 | Case 2 | Case 3 |
| Age (years) | 40 | 38 | 28 | 49 |
| Sex (M/F) | F | M | F | M |
| Duration of symptoms (years) | NA | 6 | 8 | 17 |
| Pre‐RFA serum phosphorus (mg/dL) | 1.4 | 1.2 | 1.4 | 1.0 |
| Post‐RFA (day 7) serum phosphorus (mg/dL) | NA | 3.5 | 2.6 | 2.03 |
| Pre‐RFA FGF‐23 (RU/mL) | NA | 144.9 | 162.4 | 6000 |
| Post‐RFA (day 7) FGF‐23 (RU/mL) | NA | 23 | 41 | 5500 |
| Pre‐RFA TMP/GFR (%) | 0.8 | 1.25 | 0.68 | 0.25 |
| Imaging | FDG PET‐CT | 99mTc HYNIC TOC | ||
| Site of lesion | Head, right femur | Head, right femur | Proximal shaft, left femur | Lower end, left femur |
| Size (mm) | NA | 15 × 12 | 13 × 12 | 56 × 65 |
| Histopathology | Benign mesenchymal tumor | NA | NA | Non‐ossifying fibroma |
| Duration of follow‐up after RFA (months) | 12 | 12 | 15 | 6 |
RFA = radiofrequency ablation; FGF‐23 = fibroblast growth factor‐23; TMP/GFR = ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate.